Axsome Therapeutics – company profile
📍 Who are they?
Axsome Therapeutics Inc. (NASDAQ: AXSM) is a U.S. biopharmaceutical company headquartered in New York, operating since 2012.
The company focuses on treatments for central nervous system (CNS) disorders — such as depression, mood disorders, narcolepsy and fibromyalgia.
👨⚕️ Who’s behind the company?
The founder and CEO is Dr. Herriot Tabuteau — a physician, economist, and former hedge fund manager at Avenue Capital Group.
After years in finance, he noticed that psychiatry is one of the most underserved fields of medicine.
His mission became building a company that would truly change how depression is treated.
💡 What’s the business idea?
Axsome operates under a “lean biotech” model:
- a small, highly specialised team
- full focus on psychiatric and neurological conditions
- use of accelerated FDA pathways (505(b)(2))
- combining known compounds into new, patented formulations with innovative mechanisms
This allows them to develop drugs faster and cheaper — while maintaining clinical safety.
💊 Their biggest breakthrough
⭐ Auvelity — the world’s first oral NMDA receptor antagonist approved by the FDA for major depressive disorder (MDD).
- Works much faster than traditional SSRIs — first effects often within 2–3 days
- Available by prescription and reimbursed under most U.S. plans
- In practice — the first “modern” antidepressant in over 20 years
🚀 Other key programs
- Sunosi — treatment for excessive daytime sleepiness (narcolepsy & sleep apnea)
- AXS-12 — in final-stage trials for narcolepsy
- AXS-14 — in clinical development for fibromyalgia
- AXS-05 — potential use in Alzheimer’s-related agitation
💰 Financial snapshot
- Market cap: ~USD 3.3B (Oct 2025)
- 2025E revenue: USD 250–300M
- YoY growth: +60–70%
- ~80% of shares held by major institutional investors
(including Vanguard, BlackRock, Perceptive Advisors)
🎯 Company mission
“Transforming the approach to CNS disorders.”
Axsome wants to redefine the treatment of mental health conditions — delivering therapies that work faster, more effectively, and are truly accessible to patients, rather than simply “lifting mood after several weeks.”
Auvelity – a breakthrough in depression treatment
⚙️ What is Auvelity?
Auvelity is an innovative drug developed by Axsome Therapeutics, approved by the FDA in August 2022 for the treatment of major depressive disorder (MDD) in adults.
It is the first oral NMDA antagonist — a new mechanism of action that allows for much faster mood improvement than traditional SSRIs or SNRIs.
🔬 How does it work?
🧠 Composition:
- Dextromethorphan – modulates NMDA receptors (acts on the glutamatergic system)
- Bupropion – increases dopamine and norepinephrine levels, and prolongs the activity of dextromethorphan
⚡ Effect:
- Mood improvement often within 2–3 days
- Increased energy and motivation
- Without the strong sedation or slowing typical of SSRIs
👩⚕️ Who is it for?
- Adults with major depressive disorder (MDD)
- Patients for whom traditional medications don’t work — or work too slowly
- People who need a rapid clinical effect without in-clinic administration (as required with esketamine / Spravato)
📋 The medication is prescription-only and is increasingly covered by major U.S. insurance plans.
⚖️ Clinical effectiveness
In the GEMINI and ASCEND trials:
- Significant mood improvement in >50% of patients after 1 week
- Full symptom remission in ~40% after 6 weeks
- Effects maintained in longer-term therapy (>6 months)
For comparison: traditional SSRIs usually require 4–6 weeks for a first noticeable effect.
⚠️ Most common side effects
- Insomnia (≈20%)
- Dizziness
- Dry mouth
- Slight increase in blood pressure
Notably, typical SSRI-related sexual dysfunction and daytime sedation were not observed.
💰 Price and availability
- List price: approx. $1,200–$1,400 per month
- Most insurance plans now reimburse
- Axsome offers copay-assistance programs (reducing cost to $0–$60 for patients)
- Available via major U.S. pharmacy chains such as CVS, Walgreens, Walmart, and telemedicine channels
📈 Sales and market
- 2024 sales: ~USD 175M
- 2025E: ~USD 300M (+70% YoY)
- Total U.S. market potential: > USD 4B annually at full adoption
Auvelity is currently the only oral NMDA-based antidepressant — with its main competitor being clinic-administered esketamine (Spravato – J&J).
🧭 Why is this a breakthrough?
✅ Faster action than SSRI/SNRI
✅ Oral form – easy access
✅ New mechanism – higher effectiveness in treatment-resistant depression
✅ Real, growing sales and reimbursement in the U.S.
Auvelity has opened a new chapter in depression treatment — the first in two decades.
For Axsome, it’s a foundation for growth, and for patients — a real alternative to slow-acting antidepressants.
Dr. Herriot Tabuteau – physician, investor, visionary
📍 Who is he?
Dr. Herriot Tabuteau is the founder, CEO and Chairman of Axsome Therapeutics Inc. — the company that brought the breakthrough antidepressant Auvelity to market.
He’s one of the few leaders in biotech who combines clinical medical experience with hedge-fund investment practice.
🎓 Education
🧬 M.D. — Columbia University College of Physicians and Surgeons
💼 B.A. in Economics — Columbia University
The mix of medicine and economics shaped his mindset: clinical precision + financial discipline.
💼 Early career
Before founding Axsome, Tabuteau was Chief Investment Officer at Avenue Capital Group — one of the largest hedge funds in the world (AUM > $10B).
There he analyzed hundreds of pharmaceutical companies and realized that psychiatry and neurology were among the most neglected areas of innovation.
Instead of only investing in others — he decided to build something himself.
That’s how Axsome Therapeutics was founded in 2012.
💡 His vision
🔹 Focus exclusively on brain and mental-health disorders (CNS)
🔹 Use new biological mechanisms (glutamate, NMDA, neuroplasticity)
🔹 Develop drugs faster via the FDA 505(b)(2) pathway
🔹 Keep the company “lean” — minimal structure, maximum efficiency
“We didn’t want to be just another SSRI maker.
We wanted to truly change how depression is treated.” — Dr. Tabuteau
🧭 Leadership style
✔️ Extreme control & precision — personally oversees every clinical program
✔️ Investment mindset — manages the pipeline like a portfolio
✔️ Culture of efficiency — small teams, maximum impact
✔️ Long-term focus — has not sold shares since the IPO (2015)
🏆 Key milestones
📆 2012 → Axsome Therapeutics founded
📆 2022 → FDA approval of Auvelity (first oral NMDA-targeting antidepressant)
📆 2024–2025 → Revenue exceeds $250M+ annually
📆 2025 → Axsome becomes a leader in modern psychiatry
📈 Industry reputation
📰 Media: “the man who unstuck modern psychiatry”
💼 Finance world: “a fund manager who actually built something in biotech”
📊 Investors: symbol of trust and long-term thinking
🔹 Summary
Dr. Herriot Tabuteau is a rare combination of doctor, analyst and entrepreneur.
His consistency turned Axsome into a global reference point in depression treatment — in just a decade.
🧠 He didn’t just build a company — he helped define a new direction for clinical psychiatry.
💼 Axsome Therapeutics Shareholders
📊 Shareholder structure (2025)
🏦 Institutional investors: ~79%
👥 Management & insiders: ~3.5%
📈 Retail investors: ~17%
🏦 Largest shareholders
🔹 Vanguard Group — ~8.5%
🔹 BlackRock Inc. — ~6.7%
🔹 Wellington Management — ~4%
🔹 Perceptive Advisors — ~3.4%
🔹 Broadfin Capital — ~3.8%
🔹 T. Rowe Price Associates — ~3%
➡️ Dominated by large, long-term funds — providing stable capital and lower volatility.
👨⚕️ Insiders
🔹 Dr. Herriot Tabuteau (CEO) — ~2.4%
🔹 Other executives (total) — ~1%
The CEO has not sold shares since the IPO, which the market views as a strong confidence signal.
✅ Assessment of the structure
✔️ Balanced — no single dominant shareholder
✔️ “Smart money” institutions hold the majority
✔️ Management has real skin in the game
💡 In short: a stable shareholder base, strong institutional support and leadership fully aligned with investors — long-term.
⚠️ Disclaimer
This article is for information and educational purposes only.
It does not constitute investment advice, financial guidance, or a recommendation to buy or sell any financial instruments — including shares of Axsome Therapeutics (NASDAQ: AXSM).
Before making any investment decisions, you should conduct your own analysis and consult a licensed financial advisor.
The author is not responsible for any investment decisions made based on the information contained in this material.